搜尋結果
- 前收市價11.100開市11.140買盤11.260賣出價11.480
- 今日波幅11.000 - 11.52052週波幅9.170 - 26.000成交量1.8M平均成交量1.36M
- 市值26.09BBeta值 (5年,每月)0.36市盈率 (最近12個月)不適用每股盈利 (最近12個月)-2.220
- 業績公佈日2024-08-28遠期股息及收益率不適用 & 不適用除息日不適用1年預測目標價39.24
相關股票
荣昌生物:09995.HK 港交所公告 公告及通告 业绩报告 上市文件 07 2024.05 月報表 截至二零二四年四月三十日止月份之股份發行人的證券變動月報表 26 2024.04 [海外監管公告-其他] 海外監管公告 - 華泰聯合證券有限責任公司關於榮昌生物製藥(煙台)股份有限 ...
This announcement is made by RemeGen Co., Ltd.* ( ) (the. 司. ‘‘Company ’’) on a voluntary basis. Reference is made to the announcements of the Company dated February 3, 2021 and March 23, 2021 (the ‘‘Announcements ’’), and the circular dated March 5, 2021 (the Circular ’’), in relation to the adoption of the First H ...
Purchase’’) on the market, at a consideration from approximately HK$76.90 to HK$80.00 per Share and a total consideration of approximately HK$5,500,000 in aggregate, pursuant to the First H Share Award and Trust Scheme as a long-term equity incentive for employees
Clearing HK and deposited into CCASS operated by HKSCC on June 2, 2021 and the listing of such portion of Converted H Shares on the Stock Exchange will commence at 9:00 a.m. on June 3, 2021. It is expected that the conversion and listing of Unlisted
For the relevant terms of the A Share Offering, please refer to the full text of the Issue Announcement of RemeGen Co., Ltd.* for the Initial Public Offering and Listing of Stocks on the STAR Market (《榮昌生物製藥(煙台)股份有限公司首次公開發行股票並在科創板上
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for
“Share Purchase”) on the market, at a consideration from approximately HK$21.03 to HK$26.90 per H Share and a total consideration of approximately HK$12,054,900 in aggregate, pursuant to the Second H Share Award and Trust Scheme as a long-term equity incentive for employees in the